Browsing Tag
Temcell
2 posts
Mesoblast (ASX: MSB) reports US$99m cash after stronger Ryoncil sales and lower expenditure
Mesoblast has reported higher year-on-year revenue from its approved cell therapy Ryoncil and a sharp reduction in operating cash expenditure, although sequential sales declined following a stronger June quarter.
Mesoblast (ASX: MSB; Nasdaq: MESO) CEO invests A$2.73m as Ryoncil growth shifts focus to execution
Mesoblast Chief Executive Silviu Itescu has paid A$2.73 million to increase his ownership, adding an alignment signal as Ryoncil sales and late-stage programs reshape the company.